{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:25:52Z","timestamp":1790717152067,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd002292.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000}}],"reference-count":124,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd002292.pub4","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T10:50:19Z","timestamp":1691751019000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Interventions for bullous pemphigoid"],"prefix":"10.1002","volume":"2023","author":[{"given":"Sanjay","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology; Institute of Medical Sciences, Banaras Hindu University; Varanasi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gudula","family":"Kirtschig","sequence":"additional","affiliation":[{"name":"Medical Health Centre Frauenfeld; Frauenfeld Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinayak N","family":"Anchan","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology; Institute of Medical Sciences, Banaras Hindu University; Varanasi India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Chi","family":"Chi","sequence":"additional","affiliation":[{"name":"School of Medicine, College of Medicine; Chang Gung University; Taoyuan Taiwan"},{"name":"Department of Dermatology; Chang Gung Memorial Hospital, Linkou; Taoyuan Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Taghipour","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Whittington Health NHS Trust; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Boyle","sequence":"additional","affiliation":[{"name":"National Heart & Lung Institute, Section of Inflammation and Repair; Imperial College London; London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dedee F","family":"Murrell","sequence":"additional","affiliation":[{"name":"Department of Dermatology; St George Hospital & University of New South Wales; Sydney Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2016.11.003","article-title":"A randomized double-blind trial of intravenous immunoglobulin for bullous pemphigoid","volume":"85","author":"Amagai","year":"2017","journal-title":"Journal of Dermatological Science"},{"issue":"12","key":"10.1002\/14651858.CD002292.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/archderm.143.12.1536","article-title":"A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid","volume":"143","author":"Beissert","year":"2007","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/bmj.2.6146.1190","article-title":"Azathioprine plus prednisone in treatment of pemphigoid","volume":"2","author":"Burton","year":"1978","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0004|cit4","first-page":"518","article-title":"Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: A comparative multicenter study","volume":"120","author":"Dreno","year":"1993","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"issue":"6","key":"10.1002\/14651858.CD002292.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1001\/archderm.1994.01690060083010","article-title":"Nicotinamide and tetracycline therapy of bullous pemphigoid","volume":"130","author":"Fivenson","year":"1994","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archderm.1993.01680220061016","article-title":"Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid","volume":"129","author":"Guillaume","year":"1993","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1001\/archderm.141.6.691","article-title":"Prediction of survival for patients with bullous pemphigoid. A prospective study","volume":"141","author":"Joly","year":"2005","journal-title":"Archives of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa011592","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"346","author":"Joly","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0009|cit9","first-page":"1S235","article-title":"A comparison of oral and topical corticosteroids in patients with bullous pemphigoid","volume":"129 Suppl 1 Pt","author":"Joly","year":"2002","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"issue":"7","key":"10.1002\/14651858.CD002292.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/jid.2008.412","article-title":"A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: A multicenter randomized study","volume":"129","author":"Joly","year":"2009","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0011|cit11","unstructured":"Joly P Personal communication Email communication clarifying the published report."},{"issue":"10","key":"10.1002\/14651858.CD002292.pub4-BIB0012|cit12","first-page":"881","article-title":"Effects of Jingui Shenqi Pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients","volume":"26","author":"Liu","year":"2006","journal-title":"Chinese Journal of Integrated Traditional and Western Medicine"},{"issue":"10","key":"10.1002\/14651858.CD002292.pub4-BIB0013|cit13","first-page":"925","article-title":"Treatment of bullous pemphigoid with prednisolone only: 0.75 mg\/kg\/day versus 1.25 mg\/kg\/day. A multicenter randomized study","volume":"111","author":"Morel","year":"1984","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"issue":"8401","key":"10.1002\/14651858.CD002292.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/S0140-6736(84)92565-0","article-title":"Plasma exchange in bullous pemphigoid","volume":"2","author":"Roujeau","year":"1984","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD002292.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1111\/all.13950","article-title":"Mepolizumab failed to affect bullous pemphigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study","volume":"75","author":"Simon","year":"2020","journal-title":"Allergy"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/bjd.15649","article-title":"An open, multicenter, randomized clinical study in patients with bullous pemphigoid comparing methylprednisolone and azathioprine with methylprednisolone and dapsone","volume":"177","author":"Sticherling","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"10","key":"10.1002\/14651858.CD002292.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta21100","article-title":"A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg\/day) with that of oral prednisolone (0.5 mg\/kg\/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial","volume":"21","author":"Chalmers","year":"2017","journal-title":"Health Technology Assessment"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bjd.13729","article-title":"A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mg kg(-1) daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial","volume":"173","author":"Chalmers","year":"2015","journal-title":"British Journal of Dermatology"},{"issue":"S1","key":"10.1002\/14651858.CD002292.pub4-BIB0019|cit19","first-page":"11","article-title":"Doxycycline vs. prednisolone for initial treatment of bullous pemphigoid: A pragmatic noninferiority randomized controlled trial","volume":"175","author":"Williams","year":"2016","journal-title":"British Journal of Dermatology"},{"issue":"10079","key":"10.1002\/14651858.CD002292.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/S0140-6736(17)30560-3","article-title":"Doxycycline versus prednisolone as an initial treatment strategy for bullous pemphigoid: a pragmatic, non-inferiority, randomised controlled trial","volume":"389","author":"Williams","year":"2017","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD002292.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/cpt.1111","article-title":"A randomized, first-in-human, healthy volunteer trial of sutimlimab, a humanized antibody for the specific inhibition of the classical complement pathway","volume":"104","author":"Bratko","year":"2018","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"134","key":"10.1002\/14651858.CD002292.pub4-BIB0022|cit22","first-page":"1","article-title":"Combined integrated protocol\/basket trial design for a first-in-human trial","volume":"11","author":"Derhaschnig","year":"2016","journal-title":"Orphanet Journal of Rare Diseases"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0023|cit23","unstructured":"Effect of simvastatin in combination with a superpotent topical corticosteroid in bullous pemphigoid apps.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2011-004361-32-DE"},{"issue":"389 (10083)","key":"10.1002\/14651858.CD002292.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(17)30070-3","article-title":"First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial","volume":"20","author":"Joly","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1002\/14651858.CD002292.pub4-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"WC01","DOI":"10.7860\/JCDR\/2018\/37164\/12270","article-title":"A comparative study on the efficacy of i.V. cyclophosphamide pulse versus oral cyclophosphamide in bullous pemphigoid","volume":"12","author":"Kannan","year":"2018","journal-title":"Journal of Clinical and Diagnostic Research"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0026|cit26","unstructured":"Efficacy and safety of omalizumab in bullous pemphigoid clinicaltrials.gov\/ct2\/show\/NCT00472030"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0027|cit27","unstructured":"Safety, efficacy and PK\/PD of QGE031 vs. placebo in patients with active bullous pemphigoid despite oral steroid treatment clinicaltrials.gov\/ct2\/show\/NCT01688882"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0028|cit28","unstructured":"A proof-of-concept study of topical AC-203 in patients with bullous pemphigoid clinicaltrials.gov\/ct2\/show\/NCT03286582"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0029|cit29","unstructured":"Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP) clinicaltrials.gov\/ct2\/show\/NCT05061771"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0030|cit30","unstructured":"Combined treatment with low dose systemic steroids and topical steroids in bullous pemphigoid and factors of treatment-refractory bullous pemphigoid apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-IOR-15007146"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0031|cit31","unstructured":"Use of tripterygium glycosides and nicotinamide plus minocycline for the treatment of bullous pemphigoid: A multicenter, randomized and controlled clinincal trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TRC-12003592"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0032|cit32","unstructured":"Use of oral methotrexate plus glucocorticoid for the treatment of bullous pemphigoid: a multicenter, randomized and controlled clinical trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TRC-12003593"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0033|cit33","unstructured":"Double-blind, randomized, placebo-controlled trial of AKST4290 for adjunctive treatment of mild to moderate bullous pemphigoid www.clinicaltrialsregister.eu\/ctr-search\/search?query=2019-001059-37"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0034|cit34","unstructured":"Topical steroids alone or associated with methotrexate in bullous pemphigoid (BP\/MTX) clinicaltrials.gov\/ct2\/show\/NCT02313870"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0035|cit35","unstructured":"Randomized, controlled clinical trial for low-dose interleukin-2 in the treatment of moderate to severe bullous pemphigoid apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR2000028707"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0036|cit36","unstructured":"Use of inravenous methotrexate plus glucocorticoid for the treatment of bullous pemphigoid: A multicenter, randomized and controlled clinincal trial apps.who.int\/trialsearch\/Trial2.aspx?TrialID=ChiCTR-TRC-12003538"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0037|cit37","unstructured":"Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-002912-34\/FR"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0038|cit38","unstructured":"Treatment of bullous pemphigoid with avdoralimab (IPH5401), an anti-C5aR1 monoclonal antibody clinicaltrials.gov\/ct2\/show\/NCT04563923"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0039|cit39","unstructured":"Wound dressings for pemphigus and pemphigoid clinicaltrials.gov\/ct2\/show\/NCT02365675"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0040|cit40","unstructured":"A study to evaluate the efficacy and safety of dupilumab in adult patients with bullous pemphigoid (LIBERTY-BP) clinicaltrials.gov\/ct2\/show\/NCT04206553"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0041|cit41","unstructured":"A multinational, randomized, double-blind, parallel-group, placebo-controlled study to investigate the use of benralizumab as a treatment option for patients with bullous pemphigoid (FJORD) clinicaltrials.gov\/ct2\/show\/NCT04612790"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1365-4362.1992.tb03519.x","article-title":"Bullous diseases in Malaysia: Epidemiological and natural history","volume":"31","author":"Adam","year":"1992","journal-title":"International Journal of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD002292.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/09629359891126","article-title":"Topical glucocorticoids and the skin--mechanisms of action: an update","volume":"7","author":"Ahluwalia","year":"1998","journal-title":"Mediators of Inflammation"},{"issue":"8","key":"10.1002\/14651858.CD002292.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/archderm.1977.01640080045002","article-title":"Bullous pemphigoid: Clinical and immunologic follow-up after successful treatment","volume":"113","author":"Ahmed","year":"1977","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"874108. doi: 10","DOI":"10.3389\/fimmu.2022.874108","article-title":"Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: a case series of 13 patients","volume":"13","author":"Alexandre","year":"2022","journal-title":"Frontiers of Immunology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","article-title":"Mycophenolate mofetil and its mechanisms of action","volume":"47","author":"Allison","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"595\u2013603","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD002292.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"637\u201343","DOI":"10.1038\/jid.2010.301","article-title":"Risk factors for bullous pemphigoid in the elderly: a prospective case-control study","volume":"131","author":"Bastuji-Garin","year":"2011","journal-title":"Journal of Investigative Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/archderm.1995.01690130050009","article-title":"Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group","volume":"131","author":"Bernard","year":"1995","journal-title":"Archives of Dermatology"},{"issue":"6","key":"10.1002\/14651858.CD002292.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"1191\u201397","DOI":"10.1016\/j.jaad.2014.07.052","article-title":"A population-based study of the association between bullous pemphigoid and neurologic disorders","volume":"71","author":"Brick","year":"2014","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0051|cit51","first-page":"928621. DOI: 10","article-title":"Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review","volume":"13","author":"Cao","year":"2022","journal-title":"Frontiers of Immunology"},{"issue":"9683","key":"10.1002\/14651858.CD002292.pub4-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"86\u20139","DOI":"10.1016\/S0140-6736(09)60329-9","article-title":"Avoidable waste in the production and reporting of research evidence","volume":"374","author":"Chalmers","year":"2009","journal-title":"Lancet"},{"issue":"7","key":"10.1002\/14651858.CD002292.pub4-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/77528","article-title":"Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease","volume":"6","author":"Chen","year":"2000","journal-title":"Nature Medicine"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0054|cit54","unstructured":"More about the Cochrane Skin Specialised Register skin.cochrane.org\/search-methods"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/j.0022-202X.2004.22504.x","article-title":"Mortality rate of bullous pemphigoid in a US medical centre","volume":"122","author":"Colbert","year":"2004","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0056|cit56","first-page":"169\u201386","article-title":"Non-inferiority trials: design concepts and issues \u2013the encounters of academic consultants in statistics","volume":"22","author":"Massaro","year":"2003","journal-title":"Statistics in Medicine"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/bdd.2510150208","article-title":"Bioavailability and reversible metabolism of prednisone and prednisolone in man","volume":"15","author":"Garg","year":"1994","journal-title":"Biopharmaceutics and Drug Disposition"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"754501","DOI":"10.3389\/falgy.2021.754501","article-title":"Potent anti-inflammatory effects of tetracyclines on human eosinophils","volume":"2","author":"Gehring","year":"2021","journal-title":"Frontiers in Allergy"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/1523-1747.ep12382738","article-title":"Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis","volume":"102","author":"Giudice","year":"1994","journal-title":"Journal of Investigative Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2005.06662.x","article-title":"Annual incidence and mortality of bullous pemphigoid in the Grampian Region of North-east Scotland","volume":"153","author":"Gudi","year":"2005","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1159\/000248663","article-title":"Clinical, histological and immunological studies in 50 patients with bullous pemphigoid","volume":"176","author":"Hadi","year":"1988","journal-title":"Dermatologica"},{"issue":"12","key":"10.1002\/14651858.CD002292.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1038\/jid.2013.236","article-title":"Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients","volume":"133","author":"Hall","year":"2013","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"Journal der Deutschen Dermatologischen Gesellschaft [Journal of the German Society of Dermatology]"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0064|cit64","unstructured":"Higgins JPT Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008] Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0065|cit65","unstructured":"Higgins JP Eldridge S Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jdermsci.2007.08.008","article-title":"Serum levels of IgE anti-BP180 and anti-BP230 autoantibodies in patients with bullous pemphigoid","volume":"49","author":"Ishiura","year":"2008","journal-title":"Journal of Dermatological Science"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: Is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clinical Trials"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1365-4362.1993.tb01441.x","article-title":"Chronic bullous dermatoses in China","volume":"32","author":"Jin","year":"1993","journal-title":"International Journal of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1001\/archderm.134.1.80","article-title":"Dermatological uses of high-dose intravenous immunoglobulin","volume":"134","author":"Jolles","year":"1998","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0070|cit70","unstructured":"Personal communication Email to P Joly clarifying the published report"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/jid.2012.35","article-title":"Incidence and mortality of bullous pemphigoid in France","volume":"132","author":"Joly","year":"2012","journal-title":"Journal of Investigative Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1365-2133.1994.tb13108.x","article-title":"Acquired bullous disease of childhood: Re-evaluation of diagnosis by indirect immunofluorescence examination on 1 M NaCl split skin and immunoblotting","volume":"130","author":"Kirtschig","year":"1994","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","article-title":"Rituximab and omalizumab for the treatment of bullous pemphigoid: a systematic review of the literature","volume":"20","author":"Kremer","year":"2019","journal-title":"American Journal of Clinical Dermatology"},{"issue":"12","key":"10.1002\/14651858.CD002292.pub4-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1111\/exd.13408","article-title":"Glucocorticoids: The mode of action in bullous pemphigoid","volume":"26","author":"Kubin","year":"2017","journal-title":"Experimental Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"a180","DOI":"10.1136\/bmj.a180","article-title":"Bullous pemphigoid and pemphigus vulgaris\u2014incidence and mortality in the UK: population based cohort study","volume":"337","author":"Langan","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1001\/archderm.135.1.89","article-title":"Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid","volume":"135","author":"Lebrun-Vignes","year":"1999","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-195302000-00001","article-title":"Pemphigus","volume":"32","author":"Lever","year":"1953","journal-title":"Medicine"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"109788. DOI: 10","DOI":"10.1016\/j.intimp.2023.109788","article-title":"Nine cases of refractory bullous pemphigoid treated with dupilumab and literature review","volume":"116","author":"Liang","year":"2023","journal-title":"International Immunopharmacology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"58\u201362","DOI":"10.1001\/2013.jamadermatol.376","article-title":"The associations between bullous pemphigoid and drug use: a UK case-control study","volume":"149","author":"Lloyd-Lavery","year":"2013","journal-title":"JAMA Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD002292.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2133.1987.tb04927.x","article-title":"Localization of bullous pemphigoid antibody - An indirect immunofluorescence study of 228 cases using a split-skin technique","volume":"117","author":"Logan","year":"1987","journal-title":"British Journal of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0081|cit81","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1111\/bjd.16006","article-title":"Doxycycline compared to prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial","volume":"178","author":"Mason","year":"2017","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","article-title":"Bullous pemphigoid","volume":"94","author":"Miyamoto","year":"2019","journal-title":"Anais Brasileiros de Dermatologia"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0083|cit83","unstructured":"Mohammadi O Kassim TA Azathioprine www.statpearls.com\/ArticleLibrary\/viewarticle\/18065 31194347"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/978-1-4899-7190-6_5","volume-title":"Management of Blistering Diseases","author":"Morrison","year":"1990"},{"issue":"3","key":"10.1002\/14651858.CD002292.pub4-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"479\u201385","DOI":"10.1016\/j.jaad.2011.06.032","article-title":"Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts","volume":"66","author":"Murrell","year":"2012","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD002292.pub4-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/archderm.1991.01680030098014","article-title":"Childhood bullous pemphigoid. Clinical and immunologic features, treatment, and prognosis","volume":"127","author":"Nemeth","year":"1991","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0087|cit87","unstructured":"Ogino MH Tadi P Cyclophosphamide www.statpearls.com\/ArticleLibrary\/viewarticle\/20199 31971727"},{"issue":"4","key":"10.1002\/14651858.CD002292.pub4-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1525-1470.1989.tb00910.x","article-title":"Pemphigoid in children","volume":"6","author":"Orange","year":"1989","journal-title":"Pediatric Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD002292.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.jaad.2008.07.022","article-title":"Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States","volume":"59","author":"Parker","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0090|cit90","first-page":"54","article-title":"Bullous and cicatricial pemphigoid: Clinical, pathological, and immunologic collerations","volume":"52","author":"Person","year":"1977","journal-title":"Mayo Clinic Proceedings"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/bjd.19022","article-title":"Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study","volume":"184","author":"Persson","year":"2021","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0092|cit92","first-page":"4\u201311","article-title":"Introducing a novel Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) in pemphigus","volume":"17","author":"Pf\u00fctze","year":"2007","journal-title":"European Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1186\/s13063-016-1555-2","article-title":"How to select outcome measurement instruments for outcomes included in a \u201cCore Outcome Set\u201d \u2013 a practical guideline","volume":"17","author":"Prinsen","year":"2016","journal-title":"Trials"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Pudar Hozo","year":"2005","journal-title":"BMC Medical Research Methodology"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.annder.2008.10.038","article-title":"Efficacy of rituximab in a case of refractory bullous pemphigoid","volume":"136","author":"Reguia\u00ef","year":"2009","journal-title":"Annales de Dermatologie et de Venereologie"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0096|cit96","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"4","key":"10.1002\/14651858.CD002292.pub4-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/BF00316481","article-title":"Comparative study of availability of prednisolone after intestinal infusion of prednisolone metasulfobenzoate and prednisone","volume":"44","author":"Rollin","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD002292.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/archderm.134.4.465","article-title":"High risk of death in elderly patients with extensive bullous pemphigoid","volume":"134","author":"Roujeau","year":"1998","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0099|cit99","first-page":"e13190; doi: 10","article-title":"Targeting interleukin 4 receptor \u03b1: A new approach to the treatment of cutaneous autoimmune bullous diseases?","volume":"33","author":"Parodi","year":"2020","journal-title":"Dermatol Ther"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/j.1365-2133.1979.tb11881.x","article-title":"The events leading to the death of patients with pemphigus and pemphigoid","volume":"101","author":"Savin","year":"1979","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0738-081X(87)90049-6","article-title":"Death in bullous pemphigoid","volume":"5","author":"Savin","year":"1987","journal-title":"Clinics in Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD002292.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/jid.2014.547","article-title":"Malignancies in pemphigus and pemphigoid diseases","volume":"135","author":"Schulze","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0103|cit103","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013 Available from gdt.guidelinedevelopment.org\/app\/handbook\/handbook.htm"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"611549. DOI: 10","DOI":"10.3389\/fimmu.2020.611549","article-title":"Case report: combination of omalizumab and dupilumab for recalcitrant bullous pemphigoid","volume":"11","author":"Seyed Jafari","year":"2021","journal-title":"Frontiers of Immunology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1172\/JCI109109","article-title":"The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone; a possible mechanism in the treatment of dermatitis herpetiformis","volume":"62","author":"Stendahl","year":"1977","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1251\u201354","DOI":"10.1001\/archdermatol.2010.322","article-title":"The association of bullous pemphigoid with cerebrovascular disease and dementia: a case-control study","volume":"146","author":"Taghipour","year":"2010","journal-title":"Archives of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0107|cit107","unstructured":"Tapia C Nessel TA Zito PM Cyclosporine www.statpearls.com\/ArticleLibrary\/viewarticle\/20202 29494057"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1440-0960.1984.tb00629.x","article-title":"Bullous pemphigoid: Clinico-epidemiological study of patients seen at a Singapore skin hospital","volume":"25","author":"Tham","year":"1998","journal-title":"Australasian Journal of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjd.15634","article-title":"Identifying priority areas for research into the diagnosis, treatment and prevention of cellulitis (erysipelas): results of a James Lind Alliance Priority Setting Partnership","volume":"177","author":"Thomas","year":"2017","journal-title":"British Journal of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1001\/jamadermatol.2016.3357","article-title":"Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity","volume":"153","author":"Van Beek","year":"2017","journal-title":"JAMA Dermatology"},{"issue":"4","key":"10.1002\/14651858.CD002292.pub4-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/0190-9622(92)70085-T","article-title":"Lack of predictive factors for the clinical course of bullous pemphigoid","volume":"26","author":"Venning","year":"1992","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"24","DOI":"10.2340\/00015555-2473","article-title":"The reliability, validity and responsiveness of two disease scores (BPDAI and ABSIS) for bullous pemphigoid: Which one to use?","volume":"97","author":"Wijayanti","year":"2017","journal-title":"Acta Dermato-venereologica"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1038\/jid.2015.134","article-title":"What Is a pragmatic clinical trial?","volume":"135","author":"Williams","year":"2015","journal-title":"Journal of Investigative Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0114|cit114","first-page":"1866","volume-title":"Textbook of Dermatology","volume":"3","author":"Wojnarowska","year":"1998"},{"issue":"2","key":"10.1002\/14651858.CD002292.pub4-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1046\/j.1365-2133.2002.04835.x","article-title":"Guidelines for the management of bullous pemphigoid","volume":"147","author":"Wojnarowska","year":"2002","journal-title":"British Journal of Dermatology"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s000110050215","article-title":"Dapsone hydroxylamine inhibits the LTB4-induced chemotaxis of polymorphonuclear leukocytes into human skin: Results of a pilot study","volume":"46","author":"Wozel","year":"1997","journal-title":"Inflammation Research"},{"issue":"23","key":"10.1002\/14651858.CD002292.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"13496","DOI":"10.1073\/pnas.96.23.13496","article-title":"A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window","volume":"96","author":"Yrjanheikki","year":"1999","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0118|cit118","first-page":"738907. DOI: 10","article-title":"Efficacy and safety of dupilumab in moderate-to-severe bullous pemphigoid","volume":"12","author":"Zhang","year":"2021","journal-title":"Frontiers of Immunology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0119|cit119","first-page":"48","article-title":"Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany (Comment)","volume":"131","author":"Zillikens","year":"1995","journal-title":"Archives of Dermatology"},{"issue":"1","key":"10.1002\/14651858.CD002292.pub4-BIB0120|cit120","first-page":"13","article-title":"Prospective study of treatment of bullous pemphigoid by a class I topical corticosteroid","volume":"126","author":"Zimmermann","year":"1999","journal-title":"Annales de Dermatologie et de V\u00e9n\u00e9r\u00e9ologie"},{"key":"10.1002\/14651858.CD002292.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fimmu.2018.00302","article-title":"The immunomodulatory effects of macrolides\u2014a systematic review of the underlying mechanisms","volume":"9","author":"Zimmermann","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"3","key":"10.1002\/14651858.CD002292.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1001\/archderm.138.3.385","article-title":"A systematic review of treatments for bullous pemphigoid","volume":"138","author":"Khumalo","year":"2002","journal-title":"Archives of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD002292.pub4-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002292.pub3","article-title":"Interventions for bullous pemphigoid","author":"Khumalo","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD002292.pub4-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002292.pub3","article-title":"Interventions for bullous pemphigoid","author":"Kirtschig","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:03:58Z","timestamp":1732093438000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD002292.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Skin Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":124,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd002292.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}